Research & Development
Dr. Reddy's Laboratories unveils Carmustine for Injection, USP in the US Market
18 October 2021 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (NSE:DRREDDY) (NYSE:RDY) reported on Friday the availability of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) in the US market.

The company revealed Carmustine for Injection, USP is a therapeutic equivalent generic version of BiCNU (carmustine for injection), which is approved by the US Food and Drug Administration (USFDA).

In addition, Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 ml sterile diluent, stated the company.

According to IQVIA Health, the BiCNU brand and generic market had U.S. sales of approximately USD19.4m MAT for the most recent 12 months ending in August 2021. iCNU is a trademark owned or licensed by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

Carmustine is used to treat cancer of lymphatic system, brain and certain types of cancers of bone marrow. It may be used to treat other types of cancer. It can be used alone, or together with certain other medicines as part of combination chemotherapy, added the company.



Related Headlines